Table 4.
Months | na | MISS O | MTX intolerance | Anticipatory and/or associative symptoms | Gastrointestinal toxicity | Behavioral symptoms |
---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | ||
3 | 53 | 19(3.8 %) | 10 (18.5 %) | 11 (20.8 %) | 16 (30.2 %) | 31 (58.5 %) |
6 | 54 | 13 (24.1 %) | 14 (25.5 %) | 16 (29.6 %) | 25 (46.3 %) | 33 (66.1 %) |
9 | 49 | 17 (34.7 %) | 14 (28.0 %) | 13 (26.5 %) | 20 (40.8 %) | 27 (55.1 %) |
12 | 49 | 18 (36.7 %) | 15 (30.6 %) | 9 (18.4 %) | 16 (32.7 %) | 28 (57.1 %) |
MISS, Methotrexate Intolerance Severity Score
aMISS not available for 2 patients at Month 3. In subsequent months numbers reduced by patients who withdrew (n = 5), in 1 patient MISS at 9 and 12 months not available